Cerus Corporation (FRA:CU2)

Market Cap	376.71M +12.8%
Revenue (ttm)	169.77M +13.0%
Net Income	-13.61M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	247
Open	1.943
Previous Close	2.054
Day's Range	1.943 - 1.943
52-Week Range	0.990 - 2.462
Beta	n/a
RSI	47.67
Earnings Date	Feb 27, 2026

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1991
• Employees: 630
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CU2

Financial Performance

In 2024, Cerus's revenue was $180.27 million, an increase of 15.29% compared to the previous year's $156.37 million. Losses were -$20.92 million, -44.20% less than in 2023.

Financial numbers in USD